HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (16) Citing Articles via Google Scholar Google Scholar Articles by Faessel, H. M. Articles by Burstein, A. H. Search for Related Content PubMed PubMed Citation Articles by Faessel, H. M. Articles by Burstein, A. H. Social Bookmarking                         What's this?

Multiple-Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers

From the Departments of Clinical Pharmacokinetics and Pharmacodynamics (Dr Faessel, Dr Gibbs, Mr Rohrbacher), Medical and Developmental Sciences (Dr Faessel, Dr Gibbs, Dr Clark, Mr Rohrbacher, Dr Burstein), and Statistics (Dr Stolar), Pfizer Global Research and Development, Groton, Connecticut.

Varenicline is a novel and selective 4ß2 nicotinic acetylcholine receptor partial agonist developed for smoking cessation. The primary objectives of this double-blind, placebo-controlled, dose-escalation study were to determine the pharmacokinetics, safety, and tolerability of multiple oral doses of varenicline given as tablets once (1 mg, 2 mg, and 3 mg) or twice (1 mg) daily to healthy adult smokers. Within each dose level, 8 subjects were randomized to varenicline and 4 subjects to placebo. Varenicline was well tolerated at doses up to and including 2 mg daily. Dose-proportional increases in maximum observed plasma concentrations and area under the plasma concentration-time curve from time zero to the end of the dosing interval values were observed between the 1-mg and 2-mg daily doses of varenicline. Once- and twice-daily dosing resulted, on average, in an approximate 2- and 3-fold increase in varenicline systemic exposure, respectively, compared with single dose. There was no evidence of concentration- or time-dependent changes in the pharmacokinetics of varenicline upon repeat dosing.

Key Words: Varenicline • multiple dosing • pharmacokinetics

Address for reprints: Hélène M. Faessel, PharmD, PhD, Pfizer Global Research and Development, Eastern Point Road/MS 8260-2309, Groton, CT 06340; e-mail: Helene.M.Faessel{at}pfizer.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. H. Burstein, D. J. Clark, M. O'Gorman, S. A. Willavize, T. G. Brayman, G. S. Grover, R. L. Walsky, R. S. Obach, and H. M. Faessel Lack of Pharmacokinetic and Pharmacodynamic Interactions Between a Smoking Cessation Therapy, Varenicline, and Warfarin: An In Vivo and In Vitro Study J. Clin. Pharmacol., November 1, 2007; 47(11): 1421 - 1429. [Abstract] [Full Text] [PDF]

				L. A. Potts and C. L. Garwood Varenicline: The newest agent for smoking cessation Am. J. Health Syst. Pharm., July 1, 2007; 64(13): 1381 - 1384. [Abstract] [Full Text] [PDF]